Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Bayer Aktiengesellschaft is a global life sciences company operating primarily in the pharmaceuticals, consumer health, and agricultural sciences industries. The company develops, manufactures, and markets prescription medicines, over-the-counter health products, crop protection chemicals, seeds, and biotechnology solutions. Its core revenue drivers are prescription pharmaceuticals for cardiology, oncology, women’s health, and specialty care; branded consumer health products; and agricultural inputs that support global food production.
Founded in 1863 in Germany, Bayer evolved from a chemical and dye manufacturer into a diversified life sciences company through sustained research investment and acquisitions. A defining milestone in its modern history was the 2018 acquisition of Monsanto, which significantly expanded Bayer’s agricultural portfolio while also introducing long-term legal and financial challenges related to glyphosate litigation. Bayer positions itself as an innovation-driven company with deep scientific expertise and a focus on addressing health and nutrition challenges globally.
Business Operations
Bayer operates through three primary business segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment develops patented prescription medicines, with revenue largely driven by innovative products in cardiovascular, oncology, hematology, and ophthalmology. Consumer Health focuses on non-prescription medicines, nutritional supplements, and personal health products sold through retail and digital channels. Crop Science generates revenue through seeds, traits, crop protection products, and digital farming solutions.
Operations are global, with manufacturing, research, and commercial activities across Europe, North America, Latin America, and Asia-Pacific. Bayer controls extensive R&D infrastructure, including biotechnology platforms and digital agriculture tools, and maintains strategic collaborations with research institutions and biotech companies. Key subsidiaries include Bayer CropScience AG and Bayer Consumer Care AG, which support regional and product-specific operations.
Strategic Position & Investments
Bayer’s strategic direction emphasizes innovation-led growth, portfolio optimization, and disciplined capital allocation. The company has focused on strengthening its pharmaceutical pipeline through internal R&D and selective licensing while managing the financial and legal impacts of the Monsanto acquisition. In recent years, Bayer has pursued restructuring initiatives, divestments of non-core assets, and cost-efficiency programs to improve profitability and balance sheet flexibility.
The company continues to invest in emerging technologies such as cell and gene therapy, digital health platforms, and sustainable agriculture solutions. Notable investments include expansion of biologics manufacturing, digital farming ecosystems, and next-generation crop traits designed to improve yields and climate resilience. Bayer also maintains minority stakes and partnerships with early-stage life sciences and agri-tech companies to supplement internal innovation.
Geographic Footprint
Bayer is headquartered in Leverkusen, Germany, and operates in more than 80 countries worldwide. Its largest markets include Europe, North America, Latin America, and Asia-Pacific, with particularly strong presence in the United States, Germany, Brazil, and China. The company generates a substantial portion of its revenue outside its home market, reflecting its global customer base.
Manufacturing and research facilities are distributed across Germany, the United States, Switzerland, Belgium, India, and China, among others. Bayer’s international footprint supports localized production, regulatory compliance, and market-specific product development, while also enabling global supply chain integration.
Leadership & Governance
Bayer operates under a two-tier governance structure typical of German public companies, consisting of a Management Board and a Supervisory Board. The leadership emphasizes science-driven decision-making, long-term value creation, and sustainability, while balancing innovation with regulatory and legal risk management.
Key executives include:
- Bill Anderson – Chief Executive Officer
- Wolfgang Nickl – Chief Financial Officer
- Christine Roth – Head of Consumer Health
- Stefan Oelrich – Head of Pharmaceuticals
- Rodrigo Santos – Head of Crop Science
The leadership team’s strategic vision centers on restoring growth momentum, advancing high-impact innovation, and strengthening Bayer’s credibility with investors, regulators, and society at large.